Discussion
Pancreaze (pancrelipase), an approved therapy used to manage pancreatic complications in cystic fibrosis (CF), has been added as a preferred therapy on a National Medicare Part D formulary, according to the therapy’s maker, Vivus. The move means lower out-of-pocket costs for patients receiving the medication through Medicare, the…
